Antibiotic - EV-035
| Source | SynBio Database |
|---|---|
| Organization | Emergent Biosolutions, Inc. |
| Market status | Under Development |
| Industry | Health |
| Value chain stage | Finished Product |
| Intended consumer | Government |
| Production process | Closed Production |
| Business models | B2C |
| Product categories | Medical Treatment |
| Biotech components | Bacteria |
| Organization type(s) | Public Company |
| Funding types | Shareholder Investment |
| Known funding amount | 86,000,000 CHF |
| Country of production | USA |
| Country of distribution | USA + Switzerland |
| Trading symbol | EVE |
| Trading exchange | SWX |
| Notes | Sold to Emergent BioSolutions in 2014 |